Across TCGA pan-cancer cohorts, CMC1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CMC1 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CMC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CMC1 expression acts as an unfavorable survival marker.

KIRC, SKCM, and PRAD are the cancer types where CMC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.134	0.811	<.001	30	view →
SKCM	DFS	Median	III,IV	0.029	0.613	<.001	27	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CMC1 tumor-vs-normal RNA expression · all CMC1 data types